Ethical Problems in Conducting Research in Acute Epidemics: The Pfizer Meningitis Study in Nigeria as an Illustration

Abstract

The ethics of conducting research in epidemic situations have yet to account fully for differences in the proportion and acuteness of epidemics, among other factors. While epidemics most often arise from infectious diseases, not all infectious diseases are of epidemic proportions, and not all epidemics occur acutely. These and other variations constrain the generalization of ethical decision-making and impose ethical demands on the individual researcher in a way not previously highlighted. This paper discusses a number of such constraints and impositions. It applies the ethical principles enunciated by Emmanuel et al.(1) to the controversial Pfizer study in Nigeria in order to highlight the particular ethical concerns of acute epidemic research, and suggest ways of meeting such challenges. The paper recommends that research during epidemics should be partly evaluated on its own merits in order to determine its ethical appropriateness to the specific situation. Snap decisions to conduct research during acute epidemics should be resisted. Community engagement, public notification and good information management are needed to promote the ethics of conducting research during acute epidemics. Individual consent is most at risk of being compromised, and every effort should be made to ensure that it is maintained and valid. Use of data safety management boards should be routine. Acute epidemics also present opportunities to enhance the social value of research and maximize its benefits to communities. Ethical research is possible in acute epidemics, if the potential challenges are thought of ahead of time and appropriate precautions taken.

Estimated impact of aggressive empirical antiviral treatment in containing an outbreak of pandemic influenza H1N1 in an isolated First Nations community

“…In the context of a public health urgency or emergency, clinical trials may be impossible or unethical . The primary obligation of public health and disease control professionals is to make the outbreak stop, or failing that, to minimize morbidity and mortality to the best of their ability, using tools at their disposal.…”

“…In the context of a public health urgency or emergency, clinical trials may be impossible or unethical. 21,22 The primary obligation of public health and disease control professionals is to make the outbreak stop, or failing that, to minimize morbidity and mortality to the best of their ability, using tools at their disposal. In this context, it is impossible to know with certainty what the epidemiological "counterfactual" would have been in this case; that is, we cannot know what the contour of this outbreak would have been if aggressive antiviral drug use had not been initiated in this community.…”

Anthropology in public health emergencies:what is anthropology good for?

“… 52 It also includes situations of very high insecurity; despite their connections with local communities, if a circumstance is deemed unsafe for health personnel it is likely not substantially safer for anthropologists. 53 In a similar vein, just as health campaigns have been poorly managed, misused or abused, 54 55 so the clumsy or unethical use of anthropology can poison perceptions and cause psychological or physical harm. 38 The misuse or misrepresentation of anthropology, in ignorance of professional codes of conduct, can have real consequences for individuals and health interventions.…”

Preparing for HIV Vaccine Trials in Nigeria: Building the Capacity of the Community and National Coordinating, Regulatory and Ethical Bodies

“…The Nigerian community has participated in a number of HIV prevention trials, some of which were sub optimal and led to sensitivities and mistrust such as the failed Pfizer trials of 1996 which was reported to lack IRB and NAFDAC approvals and had no documented evidence of informed consent [21,22]. However, prevention trials such as the microbicide study, a phase III double blinded randomized placebo controlled trial, approved by relevant IRBs and NAFDAC was conducted in Lagos and Port-Harcourt between 2004 and 2007 according to good clinical practice as established by the International Conference on Harmonization (ICH) [23].…”